Home » Stocks » VRNA

Verona Pharma PLC (VRNA)

Stock Price: $6.91 USD -0.21 (-2.95%)
Updated Jun 18, 2021 4:00 PM EDT - Market closed
After-hours: $7.25 +0.34 (4.92%) Jun 18, 4:07 PM
Market Cap 400.56M
Revenue (ttm) n/a
Net Income (ttm) -65.15M
Shares Out 57.97M
EPS (ttm) -1.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 18
Last Price $6.91
Previous Close $7.12
Change ($) -0.21
Change (%) -2.95%
Day's Open 7.11
Day's Range 6.74 - 7.26
Day's Volume 370,489
52-Week Range 4.40 - 15.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that ...

3 weeks ago - GlobeNewsWire

Posters highlight ensifentrine's safety profile and its potential to improve lung function and quality of life irrespective of COPD severity Posters highlight ensifentrine's safety profile and its poten...

1 month ago - GlobeNewsWire

ENHANCE Phase 3 program enrollment continues on track to complete in 2H21

1 month ago - GlobeNewsWire

LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces dat...

1 month ago - GlobeNewsWire

LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces tha...

1 month ago - GlobeNewsWire

LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, ef...

3 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces tha...

3 months ago - GlobeNewsWire

Positive Phase 2 results with pMDI ensifentrine in COPD

3 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

4 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit "µg"...

4 months ago - GlobeNewsWire

Verona Pharma PLC (NASDAQ: VRNA) has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstructiv...

4 months ago - Benzinga

Top-line results expected in 2Q 2021 Top-line results expected in 2Q 2021

5 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

5 months ago - GlobeNewsWire

Non-dilutive capital to provide further financial flexibility Non-dilutive capital to provide further financial flexibility

6 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...

7 months ago - GlobeNewsWire

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Initiated ENHANCE Phase 3 clinical trials in COPD

7 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intended Delisti...

7 months ago - GlobeNewsWire

Posters highlight ensifentrine’s potential to provide rapid benefits Posters highlight ensifentrine’s potential to provide rapid benefits

8 months ago - GlobeNewsWire

Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.

8 months ago - Zacks Investment Research

LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, ...

8 months ago - GlobeNewsWire

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSID...

8 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, ...

9 months ago - GlobeNewsWire

Publication highlights ensifentrine’s potential to provide rapid symptom relief Publication highlights ensifentrine’s potential to provide rapid symptom relief

9 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, ...

9 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, ...

9 months ago - GlobeNewsWire

LONDON and RALEIGH, N.C., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirat...

9 months ago - GlobeNewsWire

New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients

9 months ago - GlobeNewsWire

Results expected in the first half of 2021 Results expected in the first half of 2021

10 months ago - GlobeNewsWire

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

The small drugmaker reported good news about new clinical studies for its lead pipeline candidate.

10 months ago - The Motley Fool

Completed $200 million private placement post period

10 months ago - GlobeNewsWire

Is (VRNA) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) --  

10 months ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for August 6th 2020

Other stocks mentioned: OSB, PLT
10 months ago - Zacks Investment Research

LONDON and RALEIGH, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respir...

10 months ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for August 4th

Other stocks mentioned: ABG, HOME, SFM
10 months ago - Zacks Investment Research

LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, a...

10 months ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for July 31st

Other stocks mentioned: ABG, SFM, SSD
10 months ago - Zacks Investment Research

LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,  ...

10 months ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for July 29th

Other stocks mentioned: SCCO, SSD
10 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for July 28th

Other stocks mentioned: GTLS, PHM, WHR
10 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor of Verona Pharma

10 months ago - Zacks Investment Research

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. NEITHER THIS...

10 months ago - GlobeNewsWire

LONDON, United Kingdom and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company f...

11 months ago - GlobeNewsWire

Funding to support Phase 3 ENHANCE clinical program in COPD Funding to support Phase 3 ENHANCE clinical program in COPD

11 months ago - GlobeNewsWire

LONDON, July 06, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative t...

11 months ago - GlobeNewsWire

LONDON, May 12, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializ...

1 year ago - GlobeNewsWire

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic

1 year ago - GlobeNewsWire

About VRNA

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ens... [Read more...]

Industry
Biotechnology
IPO Date
Apr 27, 2017
CEO
David Zaccardelli
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
VRNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Verona Pharma stock is "Strong Buy." The 12-month stock price forecast is 19.00, which is an increase of 174.96% from the latest price.

Price Target
$19.00
(174.96% upside)
Analyst Consensus: Strong Buy